{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:13:24Z","timestamp":1787732004606,"version":"build-2784847793"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite significant therapeutic advances in improving lives of multiple myeloma (MM) patients, it remains mostly incurable, with patients ultimately becoming refractory to therapies. MM is a genetically heterogeneous disease and therapeutic resistance is driven by a complex interplay of disease pathobiology and mechanisms of drug resistance. We applied a multi-omics strategy using tumor-derived gene expression, single nucleotide variant, copy number variant, and structural variant profiles to investigate molecular subgroups in 514 newly diagnosed MM (NDMM) samples and identified 12 molecularly defined MM subgroups (MDMS1-12) with distinct genomic and transcriptomic features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our integrative approach let us identify NDMM subgroups with transversal profiles to previously described ones, based on single data types, which shows the impact of this approach for disease stratification. One key novel subgroup is our MDMS8, associated with poor clinical outcome [median overall survival, 38\u00a0months (global log-rank\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009&lt;\u20091\u2009\u00d7\u200910\n                      <jats:sup>\u22126<\/jats:sup>\n                      )], which uniquely presents a broad genomic loss (&gt;\u20099% of entire genome,\n                      <jats:italic>t<\/jats:italic>\n                      -test\n                      <jats:italic>p<\/jats:italic>\n                      value\u2009&lt;\u20091e\u22125) driving dysregulation of various transcriptional programs affecting DNA repair and cell cycle\/mitotic processes. This subgroup was validated on multiple independent datasets, and a master regulator analyses identified transcription factors controlling MDMS8 transcriptomic profile, including CKS1B and PRKDC among others, which are regulators of the DNA repair and cell cycle pathways.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Using multi-omics unsupervised clustering we were able to discover a new high-risk multiple myeloma patient segment. This high-risk group presents diverse previously known genetic markers, but also a new characteristic defined by accumulation of genomic loss which seems to drive transcriptional dysregulation of cell cycle, DNA repair and DNA damage. Finally, our work identified various master regulators, including E2F2 and CKS1B as the genes controlling these key biological pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-021-01140-5","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T04:02:39Z","timestamp":1639800159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4954-0994","authenticated-orcid":false,"given":"Mar\u00eda","family":"Ortiz-Est\u00e9vez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6756-647X","authenticated-orcid":false,"given":"Fadi","family":"Towfic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Flynt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0678-637X","authenticated-orcid":false,"given":"Nicholas","family":"Stong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7285-7885","authenticated-orcid":false,"given":"In Sock","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W. B.","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjan","family":"Thakurta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"issue":"12","key":"1140_CR1","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","volume":"125","author":"J Corre","year":"2015","unstructured":"Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? Blood. 2015;125(12):1870\u20136.","journal-title":"Blood"},{"issue":"5","key":"1140_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335\u201348.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1140_CR3","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy Jr","year":"2007","unstructured":"Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276\u201384.","journal-title":"Blood"},{"issue":"11","key":"1140_CR4","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26(11):2406\u201313.","journal-title":"Leukemia"},{"issue":"12","key":"1140_CR5","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1182\/blood-2002-11-3385","volume":"101","author":"F Magrangeas","year":"2003","unstructured":"Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood. 2003;101(12):4998\u20135006.","journal-title":"Blood"},{"issue":"6","key":"1140_CR6","doi-asserted-by":"publisher","first-page":"e66361","DOI":"10.1371\/journal.pone.0066361","volume":"8","author":"TH Chung","year":"2013","unstructured":"Chung TH, Mulligan G, Fonseca R, Chng WJ. A novel measure of chromosome instability can account for prognostic difference in multiple myeloma. PLoS ONE. 2013;8(6):e66361.","journal-title":"PLoS ONE"},{"issue":"3","key":"1140_CR7","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1182\/blood-2007-06-097774","volume":"111","author":"WJ Chng","year":"2008","unstructured":"Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood. 2008;111(3):1603\u20139.","journal-title":"Blood"},{"issue":"1","key":"1140_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2010.030296","volume":"96","author":"D Hose","year":"2011","unstructured":"Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2011;96(1):87\u201395.","journal-title":"Haematologica"},{"issue":"5","key":"1140_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/leu.2015.341","volume":"30","author":"WJ Chng","year":"2016","unstructured":"Chng WJ, Chung TH, Kumar S, Usmani S, Munshi N, Avet-Loiseau H, et al. Gene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia. 2016;30(5):1071\u20138.","journal-title":"Leukemia"},{"issue":"12","key":"1140_CR10","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1038\/s41375-018-0116-y","volume":"32","author":"MK Samur","year":"2018","unstructured":"Samur MK, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A, et al. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018;32(12):2626\u201335.","journal-title":"Leukemia"},{"issue":"1","key":"1140_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159\u201370.","journal-title":"Leukemia"},{"issue":"11","key":"1140_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","volume":"133","author":"A Thakurta","year":"2019","unstructured":"Thakurta A, Ortiz M, Blecua P, Towfic F, Corre J, Serbina NV, et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood. 2019;133(11):1217\u201321.","journal-title":"Blood"},{"issue":"26","key":"1140_CR13","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1140_CR14","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1140_CR15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020\u20138.","journal-title":"Blood"},{"issue":"14","key":"1140_CR16","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"116","author":"A Broyl","year":"2010","unstructured":"Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116(14):2543\u201353.","journal-title":"Blood"},{"issue":"1","key":"1140_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/leu.2017.197","volume":"32","author":"A Lagan\u00e0","year":"2018","unstructured":"Lagan\u00e0 A, Perumal D, Melnekoff D, Readhead B, Kidd BA, Leshchenko V, et al. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Leukemia. 2018;32(1):120\u201330.","journal-title":"Leukemia"},{"issue":"8","key":"1140_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41408-019-0221-9","volume":"9","author":"PH Hoang","year":"2019","unstructured":"Hoang PH, Cornish AJ, Dobbins SE, Kaiser M, Houlston RS. Mutational processes contributing to the development of multiple myeloma. Blood Cancer J. 2019;9(8):60.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1140_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587\u201397.","journal-title":"Blood"},{"issue":"4","key":"1140_CR20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2018.03.014","volume":"33","author":"AC Berger","year":"2018","unstructured":"Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell. 2018;33(4):690\u2013705.","journal-title":"Cancer Cell"},{"issue":"3","key":"1140_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540\u201356.","journal-title":"Cell"},{"key":"1140_CR22","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research N, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. New Engl J Med. 2016;374(2):135\u201345.","DOI":"10.1056\/NEJMoa1505917"},{"issue":"23","key":"1140_CR23","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"1140_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc.2016.124","volume":"17","author":"A Califano","year":"2017","unstructured":"Califano A, Alvarez MJ. The recurrent architecture of tumour initiation, progression and drug sensitivity. Nat Rev Cancer. 2017;17(2):116\u201330.","journal-title":"Nat Rev Cancer"},{"key":"1140_CR25","doi-asserted-by":"crossref","unstructured":"Lim WK, Lyashenko E, Califano A. Master regulators used as breast cancer metastasis classifier. Pacific symposium on biocomputing pacific symposium on Biocomputing; 2009. p. 504\u201315.","DOI":"10.1142\/9789812836939_0048"},{"issue":"11","key":"1140_CR26","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.1208949110","volume":"110","author":"Q Mo","year":"2013","unstructured":"Mo Q, Wang S, Seshan VE, Olshen AB, Schultz N, Sander C, et al. Pattern discovery and cancer gene identification in integrated cancer genomic data. Proc Natl Acad Sci USA. 2013;110(11):4245\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7418","key":"1140_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"D Koboldt","year":"2012","unstructured":"Koboldt D, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"issue":"11","key":"1140_CR28","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41375-018-0108-y","volume":"32","author":"GJ Morgan","year":"2018","unstructured":"Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, et al. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia. 2018;32(11):2435\u201344.","journal-title":"Leukemia"},{"issue":"2","key":"1140_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bjh.15800","volume":"185","author":"M Binder","year":"2019","unstructured":"Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Substratification of patients with newly diagnosed standard-risk multiple myeloma. Br J Haematol. 2019;185(2):254\u201360.","journal-title":"Br J Haematol"},{"issue":"5383","key":"1140_CR30","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1126\/science.281.5383.1680","volume":"281","author":"CY Wang","year":"1998","unstructured":"Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (New York, NY). 1998;281(5383):1680\u20133.","journal-title":"Science (New York, NY)"},{"issue":"2","key":"1140_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ijcard.2013.11.033","volume":"171","author":"Y Xiong","year":"2014","unstructured":"Xiong Y, Ren YF, Xu J, Yang DY, He XH, Luo JY, et al. Enhanced external counterpulsation inhibits endothelial apoptosis via modulation of BIRC2 and Apaf-1 genes in porcine hypercholesterolemia. Int J Cardiol. 2014;171(2):161\u20138.","journal-title":"Int J Cardiol"},{"issue":"2","key":"1140_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/gcc.10108","volume":"35","author":"MY Arcellana-Panlilio","year":"2002","unstructured":"Arcellana-Panlilio MY, Egeler RM, Ujack E, Magliocco A, Stuart GC, Robbins SM, et al. Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors. Genes Chromosomes Cancer. 2002;35(2):176\u201381.","journal-title":"Genes Chromosomes Cancer"},{"issue":"21","key":"1140_CR33","doi-asserted-by":"publisher","first-page":"31014","DOI":"10.18632\/oncotarget.8826","volume":"7","author":"FP Fiorentino","year":"2016","unstructured":"Fiorentino FP, Tokg\u00fcn E, Sol\u00e9-S\u00e1nchez S, Giampaolo S, Tokg\u00fcn O, Jauset T, et al. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Oncotarget. 2016;7(21):31014\u201328.","journal-title":"Oncotarget"},{"issue":"1","key":"1140_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg TA, Wang L, et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep. 2018;23(1):239\u201354.","journal-title":"Cell Rep"},{"issue":"24","key":"1140_CR35","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"8","key":"1140_CR36","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/ng.3593","volume":"48","author":"MJ Alvarez","year":"2016","unstructured":"Alvarez MJ, Shen Y, Giorgi FM, Lachmann A, Ding BB, Ye BH, et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat Genet. 2016;48(8):838\u201347.","journal-title":"Nat Genet"},{"issue":"7","key":"1140_CR37","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/s41588-018-0138-4","volume":"50","author":"MJ Alvarez","year":"2018","unstructured":"Alvarez MJ, Subramaniam PS, Tang LH, Grunn A, Aburi M, Rieckhof G, et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat Genet. 2018;50(7):979\u201389.","journal-title":"Nat Genet"},{"issue":"1","key":"1140_CR38","doi-asserted-by":"publisher","first-page":"e201900623","DOI":"10.26508\/lsa.201900623","volume":"3","author":"S Bersini","year":"2020","unstructured":"Bersini S, Lytle NK, Schulte R, Huang L, Wahl GM, Hetzer MW. Nup93 regulates breast tumor growth by modulating cell proliferation and actin cytoskeleton remodeling. Life Sci Alliance. 2020;3(1):e201900623.","journal-title":"Life Sci Alliance"},{"issue":"12","key":"1140_CR39","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/abbs\/gmz131","volume":"51","author":"X Ouyang","year":"2019","unstructured":"Ouyang X, Hao X, Liu S, Hu J, Hu L. Expression of Nup93 is associated with the proliferation, migration and invasion capacity of cervical cancer cells. Acta Biochim Biophys Sin. 2019;51(12):1276\u201385.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"1","key":"1140_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12885-017-3914-0","volume":"18","author":"FBA Barros","year":"2018","unstructured":"Barros FBA, Assao A, Garcia NG, Nonogaki S, Carvalho AL, Soares FA, et al. Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancer. BMC Cancer. 2018;18(1):53.","journal-title":"BMC Cancer"},{"issue":"2","key":"1140_CR41","first-page":"1921","volume":"17","author":"L Yu","year":"2019","unstructured":"Yu L, Zhao L, Wu H, Zhao H, Yu Z, He M, et al. Moesin is an independent prognostic marker for ER-positive breast cancer. Oncol Lett. 2019;17(2):1921\u201333.","journal-title":"Oncol Lett"},{"issue":"6","key":"1140_CR42","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.21873\/anticanres.12591","volume":"38","author":"Q Wang","year":"2018","unstructured":"Wang Q, Lu X, Wang J, Yang Z, Hoffman RM, Wu X. Moesin up-regulation is associated with enhanced tumor progression imaged non-invasively in an orthotopic mouse model of human glioblastoma. Anticancer Res. 2018;38(6):3267\u201372.","journal-title":"Anticancer Res"},{"issue":"6916","key":"1140_CR43","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nature01148","volume":"420","author":"S Etienne-Manneville","year":"2002","unstructured":"Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420(6916):629\u201335.","journal-title":"Nature"},{"issue":"1","key":"1140_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1182\/blood-2018-191","volume":"132","author":"F Jin","year":"2018","unstructured":"Jin F, Kumar S, Dai Y. The lysine-specific demethylase KDM4A\/JMJD2A acts as a tumor suppressor in multiple myeloma. Blood. 2018;132(1):191.","journal-title":"Blood"},{"issue":"3","key":"1140_CR45","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1111\/jcmm.14853","volume":"24","author":"Y Feng","year":"2020","unstructured":"Feng Y, Li L, Du Y, Peng X, Chen F. E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to EZH2. J Cell Mol Med. 2020;24(3):2157\u201368.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"1140_CR46","doi-asserted-by":"publisher","first-page":"e0120833","DOI":"10.1371\/journal.pone.0120833","volume":"10","author":"C Yang","year":"2015","unstructured":"Yang C, Pan H, Liu Y, Zhou X. Stably expressed housekeeping genes across developmental stages in the two-spotted spider mite, Tetranychus urticae. PLoS ONE. 2015;10(3):e0120833.","journal-title":"PLoS ONE"},{"issue":"2","key":"1140_CR47","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law CW, Chen Y, Shi W, Smyth GK. Voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29.","journal-title":"Genome Biol"},{"issue":"1","key":"1140_CR48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Methodol). 1995;57(1):289\u2013300.","journal-title":"J Roy Stat Soc Ser B (Methodol)"},{"issue":"43","key":"1140_CR49","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"1140_CR50","first-page":"1739","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics (Oxford, England). 2011;27(12):1739\u201340.","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"6","key":"1140_CR51","first-page":"882","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics (Oxford, England). 2012;28(6):882\u20133.","journal-title":"Bioinformatics (Oxford, England)"},{"key":"1140_CR52","unstructured":"Team RDC. R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2011;1:409."}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-01140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-021-01140-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-01140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T14:15:11Z","timestamp":1726323311000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-021-01140-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,18]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1186\/s12920-021-01140-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.03.458836","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-923792\/v1","asserted-by":"object"}]},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,18]]},"assertion":[{"value":"21 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BMS Corporation: Employment, Equity Ownership: MO, FT, NS, IJ, KW, MT, EF, and AT. Funding for data processing and storage provided by BMS Corporation. No disclosures or competing interest relevant to this work for authors other than what is listed above.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}